| Thomas Daniel Garrett, RPH | |
|
161 W Prairie Shopping Ctr, Hayden, ID 83835-9853 | |
| (208) 772-7864 | |
| (208) 772-7905 |
| Full Name | Thomas Daniel Garrett |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 161 W Prairie Shopping Ctr, Hayden, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578296356 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | P10085 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Daniel Garrett, RPH 161 W Prairie Shopping Ctr, Hayden, ID 83835-9853 Ph: (208) 772-7864 | Thomas Daniel Garrett, RPH 161 W Prairie Shopping Ctr, Hayden, ID 83835-9853 Ph: (208) 772-7864 |
News Archive
Sudden unexpected death (SUD) results from a malfunction of the heart and causes a rapid loss of blood flow through the body, leading to death. It is a very rapid process and may have few or no known warning signs. The overall survival rate for out-of-hospital arrest is only 5-10%. SUD is responsible for upwards of 450,000 people in the United States each year, with North Carolina experiencing an average of 32 SUD-related deaths each day.
Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules.
Immunomic Therapeutics, Inc., a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan.
New Zealand media reports on chronic pain are focusing on treatments involving opioids and cannabis at the expense of best practice non-drug treatments, researchers have found.
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.
› Verified 2 days ago
Ngoc Hoang, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 43 W Prairie Shopping Ctr, Hayden, ID 83835 Phone: 208-772-2774 | |
Chaysen Chong, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 260 W Honeysuckle Ave, Hayden, ID 83835 Phone: 208-762-0185 | |
Mr. Ryan Wesley Gibson, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 550 W Honeysuckle Ave, Hayden, ID 83835 Phone: 208-209-4081 Fax: 208-209-4057 | |
Mrs. Shawna Lynn Daniels, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8093 N Cornerstone Dr, Hayden, ID 83835 Phone: 208-762-9355 Fax: 208-762-9198 | |
Mr. Brian S Stewart, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 240 W Hayden Ave, Hayden, ID 83835 Phone: 208-772-3311 Fax: 208-772-1779 | |
Mrs. Andrea J Scott, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 161 W Prairie Shopping Ctr, Hayden, ID 83835 Phone: 208-772-7864 | |
Yvonne Preiss, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 260 W Honeysuckle Ave, Hayden, ID 83835 Phone: 208-762-0185 Fax: 208-772-0327 |